SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pick who wrote (328)9/20/1998 7:21:00 PM
From: Bleeker  Read Replies (1) of 857
 
It should be out in the a.m. I would think Monday.
But I don't think that article is the main issue
although the focus seems to be on that & Asensio
now. My sense is that even if the drug is approved
by the FDA, the company seems to be way overvalued
on a P/E basis and strictly on an earnings basis.
It's a speculative bubble driven by small investors
mostly I would guess. And now you have insider
sales and planned sales by company officers.

I'm not an authority on what the market acceptance will
be for this drug but the valuation seems unbelievably rich
based on the earnings numbers I've crunched so far. HEB
has a loss of -28 cents trailing earnings even before the
options and warrants are exercised. That places the P/E in
the hundreds before the exercise of warrants & options.

Good Luck,
Bleeker
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News